STOCK TITAN

Davita Inc Stock Price, News & Analysis

DVA NYSE

Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.

DaVita Inc. (NYSE: DVA), a Fortune 500 leader in kidney care and dialysis services, maintains this dedicated news hub for stakeholders tracking its clinical advancements and financial performance. Access consolidated updates on earnings reports, strategic partnerships, and regulatory developments shaping the company’s position in global healthcare markets.

This resource serves investors and industry observers seeking timely insights into DaVita’s operational milestones, including innovations through DaVita Clinical Research and expansions of its integrated care network. Content spans press releases on treatment protocols, Medicare reimbursement updates, and collaborations with healthcare providers.

Key categories include quarterly financial disclosures, acquisitions in outpatient care, clinical trial outcomes, and quality improvement initiatives. Bookmark this page for streamlined access to verified updates about DaVita’s efforts to advance kidney disease management across 3,000+ U.S. dialysis centers.

Rhea-AI Summary

DaVita Inc has achieved a significant milestone by becoming the first kidney care provider to operate entirely on renewable energy for its North American facilities. This initiative, completed in partnership with Longroad Energy, involved constructing a wind farm and a solar farm in Texas. The company now aims for 100% renewable energy globally by 2025 and has already reduced carbon emissions per dialysis treatment by 19%. Other sustainability efforts include installing energy-efficient systems in 1,200 centers and diverting over 6 million pounds of waste from landfills.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
none
-
Rhea-AI Summary

DaVita's 15th annual Tour DaVita event successfully raised nearly $1 million for Bridge of Life, a nonprofit dedicated to improving global healthcare. The event, held virtually from October 1–3, saw around 3,400 participants logging over 26,000 miles to raise awareness for kidney disease. Bridge of Life aims to provide healthcare services in underserved areas, especially crucial during the COVID-19 pandemic. Sponsors included AmerisourceBergen and Wells Fargo, underscoring community support for healthcare initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
none
-
Rhea-AI Summary

On November 29, 2021, DaVita Clinical Research published a study highlighting the effectiveness of mRNA COVID-19 vaccines in dialysis patients. The study found that vaccinated patients had a 78% and 73% efficacy against COVID-19 infection from Pfizer/BioNTech and Moderna vaccines, respectively. Vaccinated individuals were also less likely to experience hospitalization or death following breakthrough infections. This research is significant as it addresses a vulnerable group previously underrepresented in vaccine trials, providing reassurance regarding vaccination's protective benefits for over 500,000 Americans with end-stage kidney disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
clinical trial covid-19
Rhea-AI Summary

DaVita Clinical Research (DCR) will present eight research abstracts at the ASN Kidney Week 2021, taking place from Nov. 4-7. The event will host over 13,000 kidney care professionals discussing advancements in nephrology. DCR's studies will focus on COVID-19 prevention and improving clinical outcomes, including the effectiveness of mRNA vaccines in dialysis patients. Notable abstracts cover predictive algorithms for hospitalizations and safety of treatments in dialysis centers. DCR aims to enhance collaborative efforts in kidney disease management and clinical research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
conferences clinical trial
-
Rhea-AI Summary

In November 2021, DaVita and the American Diabetes Association (ADA) collaborate for American Diabetes Month, focusing on the link between diabetes and kidney disease. The initiative aims to educate and provide resources, having reached 35 million people to date. About 1.5 million Americans are diagnosed with diabetes annually, and 37 million live with kidney disease. The campaign promotes preventive measures and includes live discussions and access to kidney-friendly resources. DaVita serves 241,600 patients across over 3,100 outpatient dialysis centers globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none
-
News
Rhea-AI Summary

DaVita Inc. (NYSE: DVA) reported strong financial results for Q3 2021, achieving diluted earnings per share of $2.36, up 84.4% year-over-year. Consolidated revenues reached $2.938 billion, with operating income at $475 million. Operating cash flow was $567 million and free cash flow was $358 million. The company repurchased 2.731 million shares at an average cost of $123.14. Despite challenges from COVID-19 and a tough labor market, DaVita continues to deliver quality care and execute its strategic plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.52%
Tags
none
Rhea-AI Summary

DaVita Inc. (NYSE: DVA) will hold a virtual Capital Markets Day on November 16, 2021, from 10:00 a.m. to 12:00 p.m. Eastern Time. Investors can join the live webcast through a provided link on their investor website. The event will discuss the company’s strategies and performance, emphasizing its commitment to improving quality of life for patients while being one of the largest kidney care providers in the U.S. As of June 30, 2021, DaVita served over 204,300 patients across 2,828 outpatient dialysis centers in the U.S. and operates internationally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
none
-
Rhea-AI Summary

DaVita Inc. (NYSE: DVA) will hold its quarterly conference call on October 28, 2021, at 5:00 p.m. Eastern Time to discuss its third quarter results. The results will be available after market close that day. Interested parties can listen via webcast on the DaVita investor relations website, or by dialing in using the provided numbers. DaVita is a leading kidney care provider that serves over 204,300 patients at 2,828 outpatient dialysis centers in the U.S. and operates an additional 331 centers globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
none
Rhea-AI Summary

DaVita Kidney Care announces the appointment of Tina Livaudais as the new chief nursing officer (CNO) during Nephrology Nurses Week. Livaudais brings over 26 years of experience with DaVita, serving in various clinical and leadership roles. As CNO, she aims to enhance clinical excellence and professional growth for nursing staff. The company continues to focus on improving patient care, aiming to be the preferred provider and employer in the kidney care sector. DaVita operates 2,828 outpatient dialysis centers in the U.S., caring for over 204,300 patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none

FAQ

What is the current stock price of Davita (DVA)?

The current stock price of Davita (DVA) is $137.84 as of June 16, 2025.

What is the market cap of Davita (DVA)?

The market cap of Davita (DVA) is approximately 10.4B.
Davita Inc

NYSE:DVA

DVA Rankings

DVA Stock Data

10.41B
38.12M
48.62%
49.83%
5.69%
Medical Care Facilities
Services-misc Health & Allied Services, Nec
Link
United States
DENVER